Pfizer Fails To Delay Chantix Trial Despite New Study

Law360, New York (October 16, 2012, 11:22 PM EDT) -- An Alabama federal judge on Tuesday refused to grant Pfizer Inc. a stay in the upcoming trial over allegations that its smoking cessation drug Chantix was linked to depression and suicidal behavior despite the pharmaceutical giant’s new study that it said needed months for consideration.

U.S. District Judge Inge Prytz Johnson shot down Pfizer's arguments that its study, which it says "go[es] directly to the heart of plaintiff's medical causation and punitive damages claims,” was cause to delay the bellwether trial for three months.

The proceedings...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Whitely v. Pfizer Inc


Case Number

2:10-cv-01463

Court

Alabama Northern

Nature of Suit

365(Personal Inj. Prod. Liability)

Judge

Senior Judge Inge P Johnson

Date Filed

June 10, 2010

Law Firms

Companies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.